info@example.com

+1 66589 14556

Prostate Cancer: Symptoms, Diagnosis and Treatment

Prostate Cancer: Symptoms, Diagnosis and Treatment

📖 8 min read Written and medically reviewed by Dr. Alhad Naragude, MBBS, MS, DrNB Urology Last updated: September 6, 2026

Prostate cancer often causes no symptoms in its early stages. Many cancers are detected because of an elevated prostate-specific antigen (PSA) level, followed by prostate MRI and biopsy. Once cancer is confirmed, treatment is based on the tumour grade, stage, PSA, MRI findings, amount of cancer in the biopsy, age, general health and personal priorities. Low-risk disease may be safely monitored with active surveillance, while higher-risk localized disease may need surgery or radiation. Metastatic disease is usually treated with androgen deprivation therapy (ADT) combined with additional systemic treatment. The goal is to treat clinically important cancer while avoiding unnecessary treatment of indolent disease.

What is prostate cancer?

The prostate is a gland below the bladder that surrounds the first part of the urethra. Most prostate cancers are adenocarcinomas arising from glandular cells. The behaviour varies widely: some remain small and slow-growing for years, while others have a greater tendency to spread outside the prostate, to lymph nodes or to bone.

Because of this variation, the diagnosis is not complete until grade and stage are known. A tiny Grade Group 1 tumour and a metastatic Grade Group 5 cancer are both called prostate cancer but require very different conversations.

What symptoms can prostate cancer cause?

Early prostate cancer is commonly asymptomatic. Urinary frequency, nocturia, weak stream and urgency are more often caused by benign prostate enlargement than by cancer. Symptoms become more concerning when they occur with other abnormal findings.

  • Blood in urine or semen in selected cases.
  • New urinary obstruction or retention, especially with other suspicious findings.
  • Persistent bone pain, particularly back, hip or pelvic pain in advanced disease.
  • Unexplained weight loss, fatigue or anaemia in advanced disease.
  • Weakness, numbness or bladder/bowel changes from spinal cord compression — an emergency.

How is prostate cancer diagnosed?

PSA and clinical assessment

PSA is a prostate-derived protein measured in blood. A high PSA can occur with cancer, benign enlargement, inflammation, urinary retention and recent instrumentation. A newly raised value is often repeated when the clinical situation allows before proceeding to more invasive testing.

Prostate MRI

Multiparametric MRI helps identify suspicious lesions, estimate prostate volume and guide targeted biopsy. PI-RADS 1 to 5 expresses the likelihood that a lesion represents clinically significant prostate cancer; it is not itself a cancer diagnosis.

Prostate biopsy

Biopsy provides the tissue diagnosis. MRI-targeted cores are taken from suspicious lesions and systematic sampling may be added depending on the situation. Transperineal biopsy is increasingly used because it avoids passing the needle through the rectum and can reduce infectious complications.

Pathology

The pathology report gives Gleason patterns and an ISUP Grade Group from 1 to 5. Higher Grade Groups generally indicate more aggressive biology. The report also states how many cores contain cancer and how much cancer is present.

How is prostate cancer staged?

Staging asks whether disease is confined to the prostate, extends locally, involves lymph nodes or has spread to distant organs. MRI contributes to local staging. CT, bone imaging or PSMA PET/CT may be used in higher-risk disease depending on availability and clinical indication.

Broad category Meaning Typical treatment direction
Localized Confined to prostate or immediately local region without distant spread Active surveillance for selected low-risk disease, or curative surgery/radiation.
Locally advanced Extension beyond prostate and/or regional nodal involvement without distant metastases Usually multimodal therapy; radiation plus hormone therapy or surgery in selected patients.
Metastatic Spread to distant lymph nodes, bone or organs Systemic treatment centred on ADT plus treatment intensification; local/radiation treatment in selected settings.

How is localized prostate cancer treated?

Active surveillance

For many men with low-risk cancer, active surveillance is preferred. PSA, clinical review, repeat MRI and repeat biopsy are used to detect meaningful change while avoiding or delaying treatment side effects.

Radical prostatectomy

Radical prostatectomy removes the prostate and seminal vesicles, with pelvic lymph-node dissection when indicated by risk. It may be open, laparoscopic or robotic. Important long-term effects include urinary incontinence and erectile dysfunction, although recovery varies widely.

Radiation therapy

External-beam radiation and brachytherapy are established curative treatments in appropriate localized disease. ADT may be added for intermediate- or high-risk cancers depending on risk category and radiation plan.

How is metastatic prostate cancer treated?

ADT lowers testosterone because most prostate cancers depend on androgen signalling. For metastatic hormone-sensitive disease, ADT alone is generally not the modern endpoint for a fit patient; treatment is commonly intensified with an androgen-receptor pathway inhibitor and, in selected patients, chemotherapy as part of a doublet or triplet approach. Later treatment may include additional hormonal agents, chemotherapy, radioligand therapy, PARP-directed treatment for selected molecular alterations and bone-directed supportive care.

Genetic testing becomes increasingly important in high-risk and metastatic disease because inherited or tumour-specific alterations can affect treatment and may have implications for relatives.

What should treatment decisions consider?

  • Cancer risk group, Grade Group and stage.
  • PSA level and PSA density.
  • Amount of cancer on biopsy and MRI findings.
  • Age, life expectancy and other medical conditions.
  • Baseline urinary, bowel and sexual function.
  • Patient priorities regarding cancer control, continence, erections, treatment duration and follow-up burden.
  • Availability of salvage treatment if the first treatment does not eradicate the cancer.

Follow-up after treatment

PSA is the central follow-up marker. After radical prostatectomy it should fall to an undetectable or very low level. After radiation, PSA falls more gradually because the prostate remains in place. The definition of recurrence therefore differs after surgery and radiation. Follow-up also addresses continence, erections, bone health and treatment-related metabolic effects.

When to seek urgent medical care

Urgent assessment is needed for new leg weakness, numbness around the groin, loss of bladder or bowel control, rapidly worsening severe back pain, inability to pass urine, or severe uncontrolled symptoms. These may represent obstruction or spinal cord compression and should not wait for a routine appointment.

Risk groups: why PSA alone is not enough

Localized prostate cancer is commonly placed into risk groups using PSA, Grade Group and clinical/MRI stage. Tumour volume on biopsy, PSA density, MRI findings and selected genomic information can refine the discussion. This is why a PSA of 10 ng/mL does not have one universal meaning: the same PSA can accompany a small Grade Group 1 tumour, a larger higher-grade tumour, prostatitis or benign prostate enlargement.

Risk grouping helps determine whether active surveillance is appropriate, whether local treatment should be surgery or radiation, whether pelvic lymph nodes need staging/treatment, and whether radiation should be combined with androgen deprivation therapy. It also helps estimate the intensity of follow-up after treatment.

Quality of life matters in treatment choice

Cancer control is the first priority, but urinary and sexual outcomes matter because many men live for years or decades after treatment. Radical prostatectomy can cause temporary or persistent urine leakage and erectile dysfunction. Radiation can cause urinary frequency, bowel irritation and erectile dysfunction that may appear gradually. ADT can affect hot flushes, sexual function, muscle, bone and metabolic health. Baseline urinary symptoms, erectile function, age, other illnesses and personal priorities should be documented before treatment so that expectations are realistic and rehabilitation can start early.

How urologists put the prostate-cancer pieces together

No single number decides treatment. PSA estimates risk but is influenced by prostate size and benign conditions. MRI shows suspicious anatomy but does not prove cancer. Biopsy establishes the diagnosis and grade, but samples only part of the gland. Clinical stage estimates extent. The treatment decision becomes much more reliable when these pieces are interpreted together.

Finding What it contributes What it cannot tell you alone
PSA / PSA density Probability and follow-up signal Exact grade or stage
MRI / PI-RADS Location and suspicion of significant tumour Definitive diagnosis
Biopsy / Grade Group Cancer confirmation and aggressiveness Whole-gland pathology
Staging imaging Nodes, bone or other spread in appropriate-risk disease Microscopic disease below scan resolution

Consultation checklist

  • PSA results with dates so the trend can be reviewed.
  • Prostate MRI images and report.
  • Biopsy/histopathology report, including Gleason score and ISUP Grade Group.
  • PSMA PET, CT or bone-scan reports if done.
  • Current urinary symptoms and baseline continence/erectile function.
  • Medical illnesses, blood thinners and regular medicines.
  • Family history of prostate, breast, ovarian, pancreatic or related cancers.

FAQs

Does a high PSA mean I have prostate cancer?

No. PSA is prostate-specific but not cancer-specific. Enlargement, inflammation, retention and recent instrumentation can raise it. Persistent elevation is interpreted together with age, prostate volume, MRI and other risk factors.

Can prostate cancer be present with a normal PSA?

Yes. No PSA value completely excludes cancer, although risk generally rises as PSA rises. Clinical context and MRI/biopsy findings matter.

Is Gleason 6 really cancer?

Grade Group 1 cancer corresponds to Gleason 3+3=6. It is cancer histologically, but its metastatic potential is very low when truly low-risk, which is why active surveillance is often preferred.

Is robotic surgery better than open surgery for cancer control?

The robotic approach can reduce blood loss and may speed early recovery, but long-term cancer control depends more on tumour biology and surgical quality than on the robot itself.

Can prostate cancer be cured if it has spread?

Widely metastatic prostate cancer is usually treated as a chronic systemic disease rather than with an expectation of cure. Modern combinations can control disease for prolonged periods in many patients.

Related reading

References

Note: This information is for educational purposes only and is not a substitute for medical advice. Please consult your doctor for any symptoms.